Sun03242019

Robins Global News & Noticias



  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results


WESTLAKE VILLAGE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today reported the Company’s financial results for the fourth quarter and full year of 2018.
“We are pleased to report the results of our 2018 fourth quarter and full year and contemplate the possibilities in 2019, particularly in light of our streamlined focus on strategic priorities and successful equity raise,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “Our drive to bring unconventional scientific innovations to patients whose lives remain burdened by their disease without compromising safety has unlocked a pipeline of selective kinase inhibitors that target select pathways in specific tissues to treat a variety of chronic inflammatory and immunologic conditions with minimal to no systemic exposure. We are poised to begin Phase 3 enrollment for SNA-120 (pegcantratinib) later this year as a potential first-in-class, non-steroidal treatment for psoriasis and the associated pruritus. Additionally, we continue to see potential in SNA-125, our tissue-targeted JAK3/TrkA dual kinase inhibitor, for other inflammatory disorders of the skin, as well the gastrointestinal tract, the eye and the lung. Indeed, with additional funding through a business-development transaction or other means, we would plan to move SNA-125 forward with a Phase 2 trial in atopic dermatitis, as well as with a proof-of-concept study in ulcerative colitis, where the need for gut-restricted drugs with low systemic exposure is high. We are actively seeking a strategic partner for SNA-001, with positive results now in hand that provide a potential path to regulatory clearance. Our future is bright, and we look forward to translating our scientific aptitude and curiosity into new possibilities and positivity for patients who continue to suffer from autoimmune and inflammatory disorders across multiple therapeutic areas.”Business HighlightsIn February 2019, Sienna closed a follow-on public offering of 9,200,000 shares of common stock at a public offering price of $2.50 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 1,200,000 shares of common stock. Net proceeds to the Company were approximately $21.3 million, after underwriting discounts, commissions and estimated offering exp...


Posted: 2019-03-14 13:05:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.






Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Maiden Holdings, Ltd. Announces Fourth Quarter and Full Year 2018 Financial Results

Sat, 23 Mar 2019 10:12:00 GMT

PEMBROKE, Bermuda--(BUSINESS WIRE)--Maiden Holdings, Ltd. (NASDAQ: MHLD) (“Maiden” or “the Company”) today reported a fourth quarter 2018 net loss attributable to Maiden common shareholders of $269.2 ...

Sunlands Technology Group Announces Unaudited Fourth Quarter and Full Year 2018 Financial Results

Fri, 22 Mar 2019 05:22:00 GMT

2018 full year net revenues increased by 103.5% year-over-year 2018 full year gross billings (non-GAAP) increased by 35.0% year-over-year 2018 full year new student enrollments [1] increased by 35 ...

JinkoSolar Announces Fourth Quarter and Full Year 2018 Financial Results

Fri, 22 Mar 2019 03:30:00 GMT

View original content:https://www.prnewswire.com/news-releases/jinkosolar-announces-fourth-quarter-and-full-year-2018-financial-results-300816926.html SOURCE JinkoSolar Holding Co., Ltd. Markets ...

IntelGenx Reports Fourth Quarter and Full-Year 2018 Financial Results

Fri, 22 Mar 2019 02:05:00 GMT

SAINT LAURENT, Quebec, March 22, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter ...

Celyad to Announce Full Year 2018 Financial Results and Host Conference Call

Thu, 21 Mar 2019 22:59:00 GMT

MONT-SAINT-GUIBERT, Belgium, Mar 22, 2019 (GLOBE NEWSWIRE via COMTEX) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development ...

Related Bing Web Search

Dell Technologies Reports Fiscal Year 2018 Fourth Quarter ...

(Tue, 19 Mar 2019 17:20:00 GMT)

Dell Technologies Reports Fiscal Year 2018 Fourth Quarter and Full Year Financial Results

Exelon Reports Fourth Quarter and Full Year 2018 Results ...

(Tue, 19 Mar 2019 03:51:00 GMT)

“Exelon delivered another solid financial performance in 2018, earning $3.12 per share on an adjusted (non-GAAP) operating basis, which is at the midpoint of our revised full year guidance of $3.05-$3.20 per share and $0.07 above our original midpoint,” said Joe Nigro, Exelon senior executive vice president and CFO.

AAM Reports Fourth Quarter and Full Year 2018 Financial ...

(Fri, 15 Feb 2019 11:53:00 GMT)

"AAM's full year 2018 financial results reflect record sales, gross profit and operating cash flow, despite some launch and operating related challenges during the second half of the year. We ...

Merck Announces Fourth-Quarter and Full-Year 2018 ...

(Sun, 17 Mar 2019 17:43:00 GMT)

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2018.“Last year was a strong one for Merck marked by substantial progress on scientific and commercial fronts,” said Kenneth C. Frazier, chairman and chief executive officer, Merck.

Vipshop Reports Unaudited Fourth Quarter and Full Year ...

(Sun, 30 Dec 2018 23:54:00 GMT)

Full Year 2018 Financial Results. Total net revenue for the full year of 2018 increased by 15.9% year over year to RMB84.5 billion (US$12.3 billion) from RMB72.9 billion in the prior year ...

Raytheon Reports Strong Fourth Quarter and Full-Year 2018 ...

(Wed, 20 Mar 2019 10:52:00 GMT)

Raytheon Reports Strong Fourth Quarter and Full-Year 2018 Results - Strong bookings of $8.4 billion in the quarter and $32.2 billion for the year; book-to-bill ratio of 1.15 in the quarter and 1.19 for the year

CoreLogic Reports Fourth Quarter and Full-Year 2018 ...

(Thu, 21 Mar 2019 14:18:00 GMT)

Company Expands Insurance and International Footprint and Outperforms U.S. Mortgage Market Trends; Margin Expansion and Free Cash Flow Generation Highlight Strong Operating Execution. IRVINE, Calif.--(BUSINESS WIRE)-- CoreLogic (NYSE: CLGX), a leading global provider of residential property information, insight, analytics and data-enabled solutions, today reported financial results for the ...

Fresh Del Monte Produce Inc. Announces Fourth Quarter and ...

(Wed, 20 Mar 2019 09:12:00 GMT)

Fourth Quarter and Full Year Net Sales Up 10% from Previous Year. CORAL GABLES, Fla.--(BUSINESS WIRE)-- Fresh Del Monte Produce Inc. (NYSE:FDP) today reported financial results for the fourth quarter and year ended December 28, 2018.

2018 full-year results | Newsroom | BAE Systems ...

(Thu, 21 Mar 2019 07:02:00 GMT)

Today we announced the Group’s full-year results for 2018.

AK Steel Announces Fourth Quarter and Full-Year 2018 ...

(Thu, 21 Mar 2019 01:18:00 GMT)

WEST CHESTER, Ohio, Jan. 28, 2019 (GLOBE NEWSWIRE) -- AK Steel (NYSE: AKS) today reported its financial results for the fourth quarter and full-year 2018.. Fourth Quarter 2018 Highlights. Fourth quarter 2018 net income of $33.5 million, or $0.11 per diluted share; adjusted net income of $48.0 million, or $0.16 per diluted share, compared to a loss in prior year fourth quarter

Related News Story Videos From Youtube

Full Year Financial Results 2018 | Xero


Related Videos On: Full Year Financial Results 2018 | Xero


Orocobre Limited – Full-Year 2018 Financial Results WEBCAST


Related Videos On: Orocobre Limited – Full-Year 2018 Financial Results WEBCAST


Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational H


Related Videos On: Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational H


FRANCE 24 Live – International Breaking News & Top stories - 24/7 stream


Related Videos On: FRANCE 24 Live – International Breaking News & Top stories - 24/7 stream


Tesla Q3 2018 Earnings Call - Financial Results and Q&A Webcast [LIVE]


Related Videos On: Tesla Q3 2018 Earnings Call - Financial Results and Q&A Webcast [LIVE]






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.